Assuring quality of drugs by monitoring impurities

被引:57
作者
Ahuja, Satinder [1 ]
机构
[1] Ahuja Consulting, Calabash, NC 28467 USA
关键词
characterization; chiral impurity; degradation product; drug product; drug substance; isolation; profiling; selective analytical methodologies; terbutaline;
D O I
10.1016/j.addr.2006.10.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To assure the quality of drugs, impurities must be monitored carefully. It is important to understand what constitutes an impurity and to identify potential sources of such impurities. Selective analytical methods need to be developed to monitor them. It is generally desirable to profile impurities to provide a yardstick for comparative purposes. New impurities may be observed as changes are made in the synthesis, formulation, or production procedures, albeit for improving them. At times it is necessary to isolate and characterize an impurity when hyphenated methods do not yield the structure or when confirmation is necessary with an authentic material. Availability of an authentic material can also allow toxicological studies and provide a standard for routine monitoring of the drug product. (c) 2007 Published by Elsevier B.V.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 11 条
[1]  
Ahuja S, 2005, SEP SCI TECHNOL-SER, V6, P1
[2]  
Ahuja S., 2003, CHROMATOGRAPHY SEPAR
[3]  
Ahuja S., 2003, HDB ISOLATION CHARAC
[4]  
Ahuja S., 1991, CHIRAL SEPARATIONS L
[5]  
AHUJA S, 1992, ACS S SERIES, V512
[6]  
Ahuja S., 2001, HDB MODERN PHARM ANA
[7]  
Ahuja S., 1998, IMPURITIES EVALUATIO
[8]  
Ahuja S., 1992, TRACE ULTRATRACE ANA
[9]  
Ahuja S, 2000, CHIRAL SEPARATIONS C
[10]  
G?r?g S., 2000, IDENTIFICATION DETER